Ryan McMillian is a strategic finance leader and fractional Chief Financial Officer who partners with venture-backed biotech companies as they scale clinical portfolios, prepare for major financings, and evaluate strategic transactions. He works closely with founders, scientific leadership, and boards to align development strategy, capital planning, and investor messaging as organizations move from early clinical work to multi-asset execution.
Ryan has helped biotech and healthcare companies raise more than $300 million in capital, supporting financings ranging from seed through late-stage venture rounds. He specializes in building integrated operating plans that connect trial design, regulatory timelines, and portfolio prioritization to capital requirements. He is a trusted partner during periods of clinical expansion, strategic inflection, and institutional capital formation.
Ryan previously served as Chief Financial Officer and Chief Operating Officer at Wellinks, where he led a $25 million Series C financing and built the operational framework to support clinical development and commercialization. Earlier, he was Head of Finance for the U.S. region at Alexion Pharmaceuticals, acting as divisional CFO for a $2 billion rare-disease commercial business and supporting multiple product launches and pricing strategy. He began his career in leadership roles at both GE and GE Capital..
Ryan holds a B.S. in Mechanical Engineering from Oklahoma State University and an MBA from Northeastern University.
